Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 5, 2015, Pages 550-556

  Zhang, Long ^a   Celentano, David D ^a   Minh, Nguyen Le ^c   Latkin, Carl A ^a   Mehta, Shruti H ^a   Frangakis, Constantine ^a   Ha, Tran Viet ^b   Mo, Tran Thi ^b   Sripaipan, Teerada ^b   Davis, Wendy W ^a   Quan, Vu Minh ^a   Go, Vivian F ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b IL   (United States)

^c Thai Nguyen University of Agriculture and Forestry   (Viet Nam)

Author keywords

Coinfection; Diazepam; Hepatitis C; HIV; Novocaine; Persons who inject drugs

Indexed keywords

DIAZEPAM; PROCAINE;

ADULT; ARTICLE; BLOOD SAMPLING; CROSS-SECTIONAL STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREVALENCE; PRIORITY JOURNAL; SEXUALITY; STRUCTURED QUESTIONNAIRE; VIET NAM; COINFECTION; COMPLICATION; HIV INFECTIONS; NEEDLE SHARING; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE;

ADULT; COINFECTION; CROSS-SECTIONAL STUDIES; DIAZEPAM; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; MALE; NEEDLE SHARING; PREVALENCE; PROCAINE; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; VIETNAM;

EID: 84927136842     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000321     Document Type: Article

References (32)

1. Hadigan C, Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. JAMA 2011; 306:294-301.
2. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837.
3. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 8:12-22.
4. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008;48:353-367.
5. Sulkowski MS, Thomas DL. Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment. Clin Infect Dis 2005; 40 (Suppl 5):S263-S269.
6. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med 2008; 59:473-485.
7. Hammett TM, Des Jarlais DC, Kling R, Kieu BT, McNicholl JM, Wasinrapee P, et al. Controlling HIV epidemics among injection drug users: eight years of cross-border HIV prevention interventions in Vietnam and China. PLoS One 2012; 7:e43141.
8. Nguyen VT, Scannapieco M. Drug abuse in Vietnam: a critical review of the literature and implications for future research. Addiction 2008; 103:535-543.
9. Quan VM, Go VF, Nam le V, Bergenstrom A, Thuoc NP, Zenilman J, et al. Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case-control study. AIDS Care 2009; 21:7-16.
10. Vietnam Ministry of Health. Vietnam HIV/AIDS Estimates and Projections 2007-2012. Ha Noi: Ministry of Health in Vietnam, 2009; 72-73.
11. Aceijas C, Stimson GV, Hickman M, Rhodes T. Global overview of injecting drug use and HIV infection among injecting drug users. AIDS 2004; 18:2295-2303.
12. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378:571-583.
13. Clatts MC, Colón-López V, Giang le M, Goldsamt LA. Prevalence and incidence of HCV infection among Vietnam heroin users with recent onset of injection. J Urban Health 2010; 87:278-291.
14. Vlahov D, Ompad DC, Fuller CM, Nandi V. Comparison of HIV risk by duration of injection drug use. Subst Use Misuse 2011; 46:181-191.
15. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013; 19:850-858.
16. Hagan H, Pouget ER, Williams IT, Garfein RL, Strathdee SA, Hudson SM, et al. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. J Infect Dis 2010; 201:378-385.
17. Clatts MC, Giang le M, Goldsamt LA, Yi H. Novel heroin injection practices: implications for transmission of HIV and other blood borne pathogens. Am J Prev Med 2007; 32 (6 Suppl):S226-S233.
18. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat 2007; 14:371-386.
19. Go VF, Frangakis C, Le Minh N, Latkin CA, Ha TV, Mo TT, et al. Effects of an HIV peer prevention intervention on sexual and injecting risk behaviors among injecting drug users and their risk partners in Thai Nguyen, Vietnam: a randomized controlled trial. Soc Sci Med 2013; 96: 154-164.
20. Solomon SS, Srikrishnan AK, Mehta SH, Vasudevan CK, Murugavel KG, Thamburaj E, et al. High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr 2008; 49:327-332.
21. Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson KE, Vlahov D, Thomas DL. Changes in blood-borne infection risk among injection drug users. J Infect Dis 2011; 203:587-594.
22. Morano JP, Gibson BA, Altice FL. The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban setting. PLoS One 2013; 8:e64321.
23. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368:1878-1887.
24. Marinho RT, Vitor S, Velosa J. Benefits of curing hepatitis C infection. J Gastrointestin Liver Dis 2014; 23:85-90.
25. Fry CL, Bruno RB. Recent trends in benzodiazepine use by injecting drug users in Victoria and Tasmania. Drug Alcohol Rev 2002; 21:363-367.
26. Clatts M, Giang le M, Goldsamt L, Colon-Lopez V. Nonmedical use of promethazine hydrochloride among heroin injectors in Vietnam: unrecognized risks and unintended consequences. Subst Use Misuse 2010; 45:515-527.
27. Mateu-Gelabert P, Sandoval M, Meylakhs P, Wendel T, Friedman SR. Strategies to avoid opiate withdrawal: implications for HCV and HIV risks. Int J Drug Policy 2010; 21:179-185.
28. Brewer DD, Hagan H, Sullivan DG, Muth SQ, Hough ES, Feuerborn NA, Gretch DR. Social structural and behavioral underpinnings of hyperendemic hepatitis C virus transmission in drug injectors. J Infect Dis 2006; 194:764-772.
29. Latkin C, Yang C, Srikrishnan AK, Solomon S, Mehta SH, Celentano DD, et al. The relationship between social network factors, HIV, and hepatitis C among injection drug users in Chennai, India. Drug Alcohol Depend 2011; 117:50-54.
30. Go VF, Frangakis C, Nam le V, Bergenstrom A, Sripaipan T, Zenilman JM, et al. High HIV sexual risk behaviors and sexually transmitted disease prevalence among injection drug users in Northern Vietnam: implications for a generalized HIV epidemic. J Acquir Immune Defic Syndr 2006; 42:108-115.
31. Koester S, Glanz J, Barón A. Drug sharing among heroin networks: implications for HIV and hepatitis B and C prevention. AIDS Behav 2005; 9:27-39.
32. Roy E, Alary M, Morissette C, Leclerc P, Boudreau JF, Parent R, et al. High hepatitis C virus prevalence and incidence among Canadian intravenous drug users. Int J STD AIDS 2007; 18:23-27.